Andrey Zaritskey

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

H. Jean Khoury, Jörge E. Cortes, Hagop M. Kantarjian et al. · Blood · 2012 · 318 citations · Full text

Medicine, Hematology, Oncology +6

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries

Verena Hoffmann, Michele Baccarani, Joerg Hasford et al. · Leukemia · 2015 · 255 citations · Full text

Medicine, Hematology, Internal Medicine +9

Bone marrow- and subcutaneous adipose tissue-derived mesenchymal stem cells: Differences and similarities

Renata I. Dmitrieva, Izida Minullina, Olga Tarasova et al. · Cell Cycle · 2012 · 209 citations · Full text

Life Sciences, Biomedical Sciences, Cell Biology +17

Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24‐month follow‐up

Carlo Gambacorti‐Passerini, Tim H. Brümmendorf, Dong‐Wook Kim et al. · American Journal of Hematology · 2014 · 117 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Primary analysis of JUMP, a phase 3b, expanded‐access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts

Haifa Kathrin Al‐Ali, Martin Grießhammer, Lynda Foltz et al. · British Journal of Haematology · 2020 · 113 citations · Full text

Medicine, Hematology, Pharmacology +14